Cargando…
New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function
Autophagy inhibition has been proposed to be a potential therapeutic strategy for cancer, however, few autophagy inhibitors have been developed. Recent studies have indicated that lysosome and autophagy related 4B cysteine peptidase (ATG4B) are two promising targets in autophagy for cancer therapy....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352571/ https://www.ncbi.nlm.nih.gov/pubmed/32532053 http://dx.doi.org/10.3390/cancers12061523 |
_version_ | 1783557669071618048 |
---|---|
author | Fu, Yuanyuan Gu, Qianqian Luo, Li Xu, Jiecheng Luo, Yuping Xia, Fan Han, Fanghai Hong, Liang Yin, Xiao-Ming Huang, Zhiying Li, Min |
author_facet | Fu, Yuanyuan Gu, Qianqian Luo, Li Xu, Jiecheng Luo, Yuping Xia, Fan Han, Fanghai Hong, Liang Yin, Xiao-Ming Huang, Zhiying Li, Min |
author_sort | Fu, Yuanyuan |
collection | PubMed |
description | Autophagy inhibition has been proposed to be a potential therapeutic strategy for cancer, however, few autophagy inhibitors have been developed. Recent studies have indicated that lysosome and autophagy related 4B cysteine peptidase (ATG4B) are two promising targets in autophagy for cancer therapy. Although some inhibitors of either lysosome or ATG4B were reported, there are limitations in the use of these single target compounds. Considering multi-functional drugs have advantages, such as high efficacy and low toxicity, we first screened and validated a batch of compounds designed and synthesized in our laboratory by combining the screening method of ATG4B inhibitors and the identification method of lysosome inhibitors. ATG4B activity was effectively inhibited in vitro. Moreover, 163N inhibited autophagic flux and caused the accumulation of autolysosomes. Further studies demonstrated that 163N could not affect the autophagosome-lysosome fusion but could cause lysosome dysfunction. In addition, 163N diminished tumor cell viability and impaired the development of colorectal cancer in vivo. The current study findings indicate that the dual effect inhibitor 163N offers an attractive new anti-cancer drug and compounds having a combination of lysosome inhibition and ATG4B inhibition are a promising therapeutic strategy for colorectal cancer therapy. |
format | Online Article Text |
id | pubmed-7352571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73525712020-07-15 New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function Fu, Yuanyuan Gu, Qianqian Luo, Li Xu, Jiecheng Luo, Yuping Xia, Fan Han, Fanghai Hong, Liang Yin, Xiao-Ming Huang, Zhiying Li, Min Cancers (Basel) Article Autophagy inhibition has been proposed to be a potential therapeutic strategy for cancer, however, few autophagy inhibitors have been developed. Recent studies have indicated that lysosome and autophagy related 4B cysteine peptidase (ATG4B) are two promising targets in autophagy for cancer therapy. Although some inhibitors of either lysosome or ATG4B were reported, there are limitations in the use of these single target compounds. Considering multi-functional drugs have advantages, such as high efficacy and low toxicity, we first screened and validated a batch of compounds designed and synthesized in our laboratory by combining the screening method of ATG4B inhibitors and the identification method of lysosome inhibitors. ATG4B activity was effectively inhibited in vitro. Moreover, 163N inhibited autophagic flux and caused the accumulation of autolysosomes. Further studies demonstrated that 163N could not affect the autophagosome-lysosome fusion but could cause lysosome dysfunction. In addition, 163N diminished tumor cell viability and impaired the development of colorectal cancer in vivo. The current study findings indicate that the dual effect inhibitor 163N offers an attractive new anti-cancer drug and compounds having a combination of lysosome inhibition and ATG4B inhibition are a promising therapeutic strategy for colorectal cancer therapy. MDPI 2020-06-10 /pmc/articles/PMC7352571/ /pubmed/32532053 http://dx.doi.org/10.3390/cancers12061523 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fu, Yuanyuan Gu, Qianqian Luo, Li Xu, Jiecheng Luo, Yuping Xia, Fan Han, Fanghai Hong, Liang Yin, Xiao-Ming Huang, Zhiying Li, Min New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function |
title | New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function |
title_full | New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function |
title_fullStr | New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function |
title_full_unstemmed | New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function |
title_short | New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function |
title_sort | new anti-cancer strategy to suppress colorectal cancer growth through inhibition of atg4b and lysosome function |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352571/ https://www.ncbi.nlm.nih.gov/pubmed/32532053 http://dx.doi.org/10.3390/cancers12061523 |
work_keys_str_mv | AT fuyuanyuan newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT guqianqian newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT luoli newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT xujiecheng newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT luoyuping newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT xiafan newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT hanfanghai newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT hongliang newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT yinxiaoming newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT huangzhiying newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction AT limin newanticancerstrategytosuppresscolorectalcancergrowththroughinhibitionofatg4bandlysosomefunction |